Post-translational modifications of the TAK1-TAB complex

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Hirata, Yusuke ^a   Takahashi, Miki ^a   Morishita, Tohru ^a   Noguchi, Takuya ^a   Matsuzawa, Atsushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

MAP kinase; NF B; Post translational modification; TAB1; TAB2; TAB3; TAK1

Indexed keywords

CALCINEURIN; INTERLEUKIN 1 RECEPTOR; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PROTEIN TAB; RING FINGER PROTEIN; SYNAPTOPHYSIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ACETYLATION; ACYLATION; ADENOID CYSTIC CARCINOMA; APOPTOSIS; AUTOPHAGY; COMPLEX FORMATION; DEPHOSPHORYLATION; HUMAN; MASS SPECTROMETRY; METHYLATION; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SUMOYLATION; UBIQUITINATION; WNT SIGNALING PATHWAY; BIOLOGICAL MODEL; ENZYME ACTIVATION; METABOLISM; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ENZYME ACTIVATION; HUMANS; MAP KINASE KINASE KINASES; MODELS, BIOLOGICAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 85010777979     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010205     Document Type: Review

References (120)

1. Yamaguchi, K.; Shirakabe, K.; Shibuya, H.; Irie, K.; Oishi, I.; Ueno, N.; Taniguchi, T.; Nishida, E.; Matsumoto, K. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995, 270, 2008–2011.
2. Dai, L.; Aye Thu, C.; Liu, X.Y.; Xi, J.; Cheung, P.C. TAK1, more than just innate immunity. IUBMB Life 2012, 64, 825–834.
3. Ajibade, A.A.; Wang, H.Y.; Wang, R.F. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 2013, 34, 307–316.
4. Oeckinghaus, A.; Hayden, M.S.; Ghosh, S. Crosstalk in NF-B signaling pathways. Nat. Immunol. 2011, 12, 695–708.
5. Cheung, P.C.; Campbell, D.G.; Nebreda, A.R.; Cohen, P. Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J. 2003, 22, 5793–5805.
6. Hinz, M.; Stilmann, M.; Arslan, S.C.; Khanna, K.K.; Dittmar, G.; Scheidereit, C. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-B activation. Mol. Cell 2010, 40, 63–74.
7. Xia, Z.P.; Sun, L.; Chen, X.; Pineda, G.; Jiang, X.; Adhikari, A.; Zeng, W.; Chen, Z.J. Direct activation of protein kinases by unanchored polyubiquitin chains. Nature 2009, 461, 114–119.
8. Cheung, P.C.; Nebreda, A.R.; Cohen, P. TAB3, a new binding partner of the protein kinase TAK1. Biochem. J. 2004, 378, 27–34.
9. Ishitani, T.; Takaesu, G.; Ninomiya-Tsuji, J.; Shibuya, H.; Gaynor, R.B.; Matsumoto, K. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J. 2003, 22, 6277–6288.
10. Munoz-Sanjuan, I.; Bell, E.; Altmann, C.R.; Vonica, A.; Brivanlou, A.H. Gene profiling during neural induction in Xenopus laevis: Regulation of BMP signaling by post-transcriptional mechanisms and TAB3, a novel TAK1-binding protein. Development 2002, 129, 5529–5540.
11. Shibuya, H.; Yamaguchi, K.; Shirakabe, K.; Tonegawa, A.; Gotoh, Y.; Ueno, N.; Irie, K.; Nishida, E.; Matsumoto, K. TAB1: An activator of the TAK1 MAPKKK in TGF-β signal transduction. Science 1996, 272, 1179–1182.
12. Takaesu, G.; Kishida, S.; Hiyama, A.; Yamaguchi, K.; Shibuya, H.; Irie, K.; Ninomiya-Tsuji, J.; Matsumoto, K. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 2000, 5, 649–658.
13. Ono, K.; Ohtomo, T.; Sato, S.; Sugamata, Y.; Suzuki, M.; Hisamoto, N.; Ninomiya-Tsuji, J.; Tsuchiya, M.; Matsumoto, K. An evolutionarily conserved motif in the TAB1 C-terminal region is necessary for interaction with and activation of TAK1 MAPKKK. J. Biol. Chem. 2001, 276, 24396–24400.
14. Besse, A.; Lamothe, B.; Campos, A.D.; Webster, W.K.; Maddineni, U.; Lin, S.C.; Wu, H.; Darnay, B.G. TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J. Biol. Chem. 2007, 282, 3918–3928.
15. Holtmann, H.; Enninga, J.; Kalble, S.; Thiefes, A.; Dorrie, A.; Broemer, M.; Winzen, R.; Wilhelm, A.; Ninomiya-Tsuji, J.; Matsumoto, K., et al. The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation. J. Biol. Chem. 2001, 276, 3508–3516.
16. Sakurai, H.; Nishi, A.; Sato, N.; Mizukami, J.; Miyoshi, H.; Sugita, T. TAK1–TAB1 fusion protein: A novel constitutively active mitogen-activated protein kinase kinase kinase that stimulates AP-1 and NF-B signaling pathways. Biochem. Biophys. Res. Commun. 2002, 297, 1277–1281.
17. Brown, K.; Vial, S.C.; Dedi, N.; Long, J.M.; Dunster, N.J.; Cheetham, G.M. Structural basis for the interaction of TAK1 kinase with its activating protein TAB1. J. Mol. Biol. 2005, 354, 1013–1020.
18. Ono, K.; Ohtomo, T.; Ninomiya-Tsuji, J.; Tsuchiya, M. A dominant negative TAK1 inhibits cellular fibrotic responses induced by TGF-β. Biochem. Biophys. Res. Commun. 2003, 307, 332–337.
19. Sakurai, H.; Miyoshi, H.; Mizukami, J.; Sugita, T. Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett. 2000, 474, 141–145.
20. Conner, S.H.; Kular, G.; Peggie, M.; Shepherd, S.; Schuttelkopf, A.W.; Cohen, P.; Van Aalten, D.M. TAK1-binding protein 1 is a pseudophosphatase. Biochem. J. 2006, 399, 427–434.
21. Wang, C.; Deng, L.; Hong, M.; Akkaraju, G.R.; Inoue, J.; Chen, Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412, 346–351.
22. Wertz, I.E.; O’Rourke, K.M.; Zhou, H.; Eby, M.; Aravind, L.; Seshagiri, S.; Wu, P.; Wiesmann, C.; Baker, R.; Boone, D.L., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-B signalling. Nature 2004, 430, 694–699.
23. Kanayama, A.; Seth, R.B.; Sun, L.; Ea, C.K.; Hong, M.; Shaito, A.; Chiu, Y.H.; Deng, L.; Chen, Z.J. TAB2 and TAB3 activate the NF-B pathway through binding to polyubiquitin chains. Mol. Cell 2004, 15, 535–548.
24. Lee, T.H.; Shank, J.; Cusson, N.; Kelliher, M.A. The kinase activity of Rip1 is not required for tumor necrosis factor-α-induced IB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J. Biol. Chem. 2004, 279, 33185–33191.
25. Kulathu, Y.; Akutsu, M.; Bremm, A.; Hofmann, K.; Komander, D. Two-sided ubiquitin binding explains specificity of the TAB2 NZF domain. Nat. Struct. Mol. Biol. 2009, 16, 1328–1330.
26. Sato, Y.; Yoshikawa, A.; Yamashita, M.; Yamagata, A.; Fukai, S. Structural basis for specific recognition of Lys 63-linked polyubiquitin chains by NZF domains of TAB2 and TAB3. EMBO J. 2009, 28, 3903–3909.
27. Symons, A.; Beinke, S.; Ley, S.C. Map kinase kinase kinases and innate immunity. Trends Immunol. 2006, 27, 40–48.
28. Deng, L.; Wang, C.; Spencer, E.; Yang, L.; Braun, A.; You, J.; Slaughter, C.; Pickart, C.; Chen, Z.J. Activation of the IB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000, 103, 351–361.
29. Sun, L.; Deng, L.; Ea, C.K.; Xia, Z.P.; Chen, Z.J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol. Cell 2004, 14, 289–301.
30. Shinohara, H.; Yasuda, T.; Aiba, Y.; Sanjo, H.; Hamadate, M.; Watarai, H.; Sakurai, H.; Kurosaki, T. PKC β regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J. Exp. Med. 2005, 202, 1423–1431.
31. Sorrentino, A.; Thakur, N.; Grimsby, S.; Marcusson, A.; von Bulow, V.; Schuster, N.; Zhang, S.; Heldin, C.H.; Landstrom, M. The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat. Cell Biol. 2008, 10, 1199–1207.
32. Yamashita, M.; Fatyol, K.; Jin, C.; Wang, X.; Liu, Z.; Zhang, Y.E. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β. Mol. Cell 2008, 31, 918–924.
33. Yamaguchi, K.; Nagai, S.; Ninomiya-Tsuji, J.; Nishita, M.; Tamai, K.; Irie, K.; Ueno, N.; Nishida, E.; Shibuya, H.; Matsumoto, K. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1–TAK1 in the BMP signaling pathway. EMBO J. 1999, 18, 179–187.
34. Lu, M.; Lin, S.C.; Huang, Y.; Kang, Y.J.; Rich, R.; Lo, Y.C.; Myszka, D.; Han, J.; Wu, H. XIAP induces NF-B activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol. Cell 2007, 26, 689–702.
35. Wu, Z.H.; Wong, E.T.; Shi, Y.; Niu, J.; Chen, Z.; Miyamoto, S.; Tergaonkar, V. ATM-and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol. Cell 2010, 40, 75–86.
36. Yang, Y.; Xia, F.; Hermance, N.; Mabb, A.; Simonson, S.; Morrissey, S.; Gandhi, P.; Munson, M.; Miyamoto, S.; Kelliher, M.A. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-B and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol. Cell. Biol. 2011, 31, 2774–2786.
37. Ishitani, T.; Ninomiya-Tsuji, J.; Nagai, S.; Nishita, M.; Meneghini, M.; Barker, N.; Waterman, M.; Bowerman, B.; Clevers, H.; Shibuya, H., et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between β-catenin and transcription factor TCF. Nature 1999, 399, 798–802.
38. Ishitani, T.; Kishida, S.; Hyodo-Miura, J.; Ueno, N.; Yasuda, J.; Waterman, M.; Shibuya, H.; Moon, R.T.; Ninomiya-Tsuji, J.; Matsumoto, K. The TAK1–NLK mitogen-activated protein kinase cascade functions in the Wnt-5a/Ca2+ pathway to antagonize Wnt/β-catenin signaling. Mol. Cell. Biol. 2003, 23, 131–139.
39. Kanei-Ishii, C.; Ninomiya-Tsuji, J.; Tanikawa, J.; Nomura, T.; Ishitani, T.; Kishida, S.; Kokura, K.; Kurahashi, T.; Ichikawa-Iwata, E.; Kim, Y., et al. Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev. 2004, 18, 816–829.
40. Kurahashi, T.; Nomura, T.; Kanei-Ishii, C.; Shinkai, Y.; Ishii, S. The Wnt–NLK signaling pathway inhibits A-Myb activity by inhibiting the association with coactivator CBP and methylating histone H3. Mol. Biol. Cell 2005, 16, 4705–4713.
41. Smit, L.; Baas, A.; Kuipers, J.; Korswagen, H.; van de Wetering, M.; Clevers, H. Wnt activates the Tak1/Nemo-like kinase pathway. J. Biol. Chem. 2004, 279, 17232–17240.
42. Culver, C.; Sundqvist, A.; Mudie, S.; Melvin, A.; Xirodimas, D.; Rocha, S. Mechanism of hypoxia-induced NF-B. Mol. Cell. Biol. 2010, 30, 4901–4921.
43. Blanco, S.; Santos, C.; Lazo, P.A. Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1. Mol. Cell. Biol. 2007, 27, 7273–7283.
44. Melvin, A.; Mudie, S.; Rocha, S. Further insights into the mechanism of hypoxia-induced NF-B. Cell Cycle 2011, 10, 879–882.
45. Huangfu, W.C.; Omori, E.; Akira, S.; Matsumoto, K.; Ninomiya-Tsuji, J. Osmotic stress activates the TAK1–JNK pathway while blocking TAK1-mediated NF-B activation: TAO2 regulates TAK1 pathways. J. Biol. Chem. 2006, 281, 28802–28810.
46. Chen, Z.; Shen, X.; Shen, F.; Zhong, W.; Wu, H.; Liu, S.; Lai, J. TAK1 activates AMPK-dependent cell death pathway in hydrogen peroxide-treated cardiomyocytes, inhibited by heat shock protein-70. Mol. Cell. Biochem. 2013, 377, 35–44.
47. Herrero-Martin, G.; Hoyer-Hansen, M.; Garcia-Garcia, C.; Fumarola, C.; Farkas, T.; Lopez-Rivas, A.; Jaattela, M. TAK1 activates AMPK-dependent cytoprotective autophagy in trail-treated epithelial cells. EMBO J. 2009, 28, 677–685.
48. Kim, S.Y.; Jeong, S.; Jung, E.; Baik, K.H.; Chang, M.H.; Kim, S.A.; Shim, J.H.; Chun, E.; Lee, K.Y. AMP-activated protein kinase-α1 as an activating kinase of TGF-β-activated kinase 1 has a key role in inflammatory signals. Cell Death Dis. 2012, 3, e357.
49. Hamidi, A.; von Bulow, V.; Hamidi, R.; Winssinger, N.; Barluenga, S.; Heldin, C.H.; Landstrom, M. Polyubiquitination of transforming growth factor β (TGF-β)-associated kinase 1 mediates nuclear factor-B activation in response to different inflammatory stimuli. J. Biol. Chem. 2012, 287, 123–133.
50. Liang, L.; Fan, Y.; Cheng, J.; Cheng, D.; Zhao, Y.; Cao, B.; Ma, L.; An, L.; Jia, W.; Su, X., et al. TAK1 ubiquitination regulates doxorubicin-induced NF-B activation. Cell. Signal. 2013, 25, 247–254.
51. Fan, Y.; Shi, Y.; Liu, S.; Mao, R.; An, L.; Zhao, Y.; Zhang, H.; Zhang, F.; Xu, G.; Qin, J., et al. Lys48-linked TAK1 polyubiquitination at lysine-72 downregulates TNFα-induced NF-B activation via mediating TAK1 degradation. Cell. Signal. 2012, 24, 1381–1389.
52. Fan, Y.; Yu, Y.; Mao, R.; Zhang, H.; Yang, J. TAK1 Lys-158 but not Lys-209 is required for IL-1β-induced Lys63-linked TAK1 polyubiquitination and IKK/NF-B activation. Cell. Signal. 2011, 23, 660–665.
53. Fan, Y.; Yu, Y.; Shi, Y.; Sun, W.; Xie, M.; Ge, N.; Mao, R.; Chang, A.; Xu, G.; Schneider, M.D., et al. Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor α-and interleukin-1β-induced IKK/NF-B and JNK/AP-1 activation. J. Biol. Chem. 2010, 285, 5347–5360.
54. Mao, R.; Fan, Y.; Mou, Y.; Zhang, H.; Fu, S.; Yang, J. TAK1 lysine 158 is required for TGF-β-induced TRAF6-mediated Smad-independent IKK/NF-B and JNK/AP-1 activation. Cell. Signal. 2011, 23, 222–227.
55. Li, Q.; Yan, J.; Mao, A.P.; Li, C.; Ran, Y.; Shu, H.B.; Wang, Y.Y. Tripartite motif 8 (TRIM8) modulates TNFα-and IL-1β-triggered NF-B activation by targeting TAK1 for K63-linked polyubiquitination. Proc. Natl. Acad. Sci. USA 2011, 108, 19341–19346.
56. Lamb, A.; Chen, J.; Blanke, S.R.; Chen, L.F. Helicobacter pylori activates NF-B by inducing Ubc13-mediated ubiquitination of lysine 158 of TAK1. J. Cell. Biochem. 2013, 114, 2284–2292.
57. Yu, Y.; Ge, N.; Xie, M.; Sun, W.; Burlingame, S.; Pass, A.K.; Nuchtern, J.G.; Zhang, D.; Fu, S.; Schneider, M.D., et al. Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NF-B and AP-1 activation as well as IL-6 gene expression. J. Biol. Chem. 2008, 283, 24497–24505.
58. Paquette, N.; Conlon, J.; Sweet, C.; Rus, F.; Wilson, L.; Pereira, A.; Rosadini, C.V.; Goutagny, N.; Weber, A.N.; Lane, W.S., et al. Serine/threonine acetylation of TGF-β-activated kinase (TAK1) by Yersinia Pestis YopJ inhibits innate immune signaling. Proc. Natl. Acad. Sci. USA 2012, 109, 12710–12715.
59. Xiao, Y.; Jin, J.; Chang, M.; Nakaya, M.; Hu, H.; Zou, Q.; Zhou, X.; Brittain, G.C.; Cheng, X.; Sun, S.C. TPL2 mediates autoimmune inflammation through activation of the TAK1 axis of IL-17 signaling. J. Exp. Med. 2014, 211, 1689–1702.
60. Zheng, H.; Li, Q.; Chen, R.; Zhang, J.; Ran, Y.; He, X.; Li, S.; Shu, H.B. The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor-and interleukin-1-induced nuclear factor-B activation by dephosphorylating the protein kinase TAK1. J. Biol. Chem. 2013, 288, 819–825.
61. Kajino, T.; Ren, H.; Iemura, S.; Natsume, T.; Stefansson, B.; Brautigan, D.L.; Matsumoto, K.; Ninomiya-Tsuji, J. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J. Biol. Chem. 2006, 281, 39891–39896.
62. Hanada, M.; Ninomiya-Tsuji, J.; Komaki, K.; Ohnishi, M.; Katsura, K.; Kanamaru, R.; Matsumoto, K.; Tamura, S. Regulation of the TAK1 signaling pathway by protein phosphatase 2C. J. Biol. Chem. 2001, 276, 5753–5759.
63. Li, M.G.; Katsura, K.; Nomiyama, H.; Komaki, K.; Ninomiya-Tsuji, J.; Matsumoto, K.; Kobayashi, T.; Tamura, S. Regulation of the interleukin-1-induced signaling pathways by a novel member of the protein phosphatase 2C family (PP2Cepsilon). J. Biol. Chem. 2003, 278, 12013–12021.
64. Kim, S.I.; Kwak, J.H.; Wang, L.; Choi, M.E. Protein phosphatase 2A is a negative regulator of transforming growth factor-β1-induced TAK1 activation in mesangial cells. J. Biol. Chem. 2008, 283, 10753–10763.
65. Liu, Q.; Busby, J.C.; Molkentin, J.D. Interaction between TAK1–TAB1–TAB2 and RCAN1–calcineurin defines a signalling nodal control point. Nat. Cell Biol. 2009, 11, 154–161.
66. Kishimoto, K.; Matsumoto, K.; Ninomiya-Tsuji, J. TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J. Biol. Chem. 2000, 275, 7359–7364.
67. Yamazaki, K.; Gohda, J.; Kanayama, A.; Miyamoto, Y.; Sakurai, H.; Yamamoto, M.; Akira, S.; Hayashi, H.; Su, B.; Inoue, J. Two mechanistically and temporally distinct NF-B activation pathways in IL-1 signaling. Sci. Signal. 2009, 2, ra66.
68. Sun, X.; Wang, Y.; Yang, S.; Ren, F.; Xia, Y.; Chang, Z. Activation of TAK1 by Sef-S induces apoptosis in 293T cells. Cell. Signal. 2013, 25, 2039–2046.
69. Kobayashi, Y.; Mizoguchi, T.; Take, I.; Kurihara, S.; Udagawa, N.; Takahashi, N. Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J. Biol. Chem. 2005, 280, 11395–11403.
70. Ouyang, C.; Nie, L.; Gu, M.; Wu, A.; Han, X.; Wang, X.; Shao, J.; Xia, Z. Transforming growth factor (TGF)-β-activated kinase 1 (TAK1) activation requires phosphorylation of serine 412 by protein kinase a catalytic subunit α (PKACα) and X-linked protein kinase (PRKX). J. Biol. Chem. 2014, 289, 24226–24237.
71. Gu, M.; Ouyang, C.; Lin, W.; Zhang, T.; Cao, X.; Xia, Z.; Wang, X. Phosphatase holoenzyme PP1/GADD34 negatively regulates TLR response by inhibiting TAK1 serine 412 phosphorylation. J. Immunol. 2014, 192, 2846–2856.
72. Zhang, D.; Xu, Z.; Tao, T.; Liu, X.; Sun, X.; Ji, Y.; Han, L.; Qiu, H.; Zhu, G.; Shen, Y., et al. Modification of TAK1 by O-linked N-acetylglucosamine facilitates TAK1 activation and promotes M1 macrophage polarization. Cell. Signal. 2016, 28, 1742–1752.
73. Chen, I.T.; Hsu, P.H.; Hsu, W.C.; Chen, N.J.; Tseng, P.H. Polyubiquitination of transforming growth factor β-activated kinase 1 (TAK1) at lysine 562 residue regulates TLR4-mediated JNK and p38 MAPK activation. Sci. Rep. 2015, 5, 12300.
74. Yang, Z.; Xian, H.; Hu, J.; Tian, S.; Qin, Y.; Wang, R.F.; Cui, J. USP18 negatively regulates NF-B signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms. Sci. Rep. 2015, 5, 12738.
75. Liu, X.; Li, H.; Zhong, B.; Blonska, M.; Gorjestani, S.; Yan, M.; Tian, Q.; Zhang, D.E.; Lin, X.; Dong, C. USP18 inhibits NF-B and NFAT activation during Th17 differentiation by deubiquitinating the TAK1-TAB1 complex. J. Exp. Med. 2013, 210, 1575–1590.
76. Fan, Y.H.; Yu, Y.; Mao, R.F.; Tan, X.J.; Xu, G.F.; Zhang, H.; Lu, X.B.; Fu, S.B.; Yang, J. USP4 targets TAK1 to downregulate TNFα-induced NF-B activation. Cell Death Differ. 2011, 18, 1547–1560.
77. Reiley, W.W.; Jin, W.; Lee, A.J.; Wright, A.; Wu, X.; Tewalt, E.F.; Leonard, T.O.; Norbury, C.C.; Fitzpatrick, L.; Zhang, M., et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase TAK1 and prevents abnormal T cell responses. J. Exp. Med. 2007, 204, 1475–1485.
78. Ahmed, N.; Zeng, M.; Sinha, I.; Polin, L.; Wei, W.Z.; Rathinam, C.; Flavell, R.; Massoumi, R.; Venuprasad, K. The E3 ligase itch and deubiquitinase Cyld act together to regulate TAK1 and inflammation. Nat. Immunol. 2011, 12, 1176–1183.
79. Charlaftis, N.; Suddason, T.; Wu, X.; Anwar, S.; Karin, M.; Gallagher, E. The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines. EMBO J. 2014, 33, 2581–2596.
80. Pathak, S.; Borodkin, V.S.; Albarbarawi, O.; Campbell, D.G.; Ibrahim, A.; van Aalten, D.M. O-GlcNAcylation of TAB1 modulates TAK1-mediated cytokine release. EMBO J. 2012, 31, 1394–1404.
81. Mendoza, H.; Campbell, D.G.; Burness, K.; Hastie, J.; Ronkina, N.; Shim, J.H.; Arthur, J.S.; Davis, R.J.; Gaestel, M.; Johnson, G.L., et al. Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. Biochem. J. 2008, 409, 711–722.
82. Yang, C.Y.; Li, J.P.; Chiu, L.L.; Lan, J.L.; Chen, D.Y.; Chuang, H.C.; Huang, C.Y.; Tan, T.H. Dual-specificity phosphatase 14 (DUSP14/MKP6) negatively regulates TCR signaling by inhibiting TAB1 activation. J. Immunol. 2014, 192, 1547–1557.
83. Wolf, A.; Beuerlein, K.; Eckart, C.; Weiser, H.; Dickkopf, B.; Muller, H.; Sakurai, H.; Kracht, M. Identification and functional characterization of novel phosphorylation sites in TAK1-binding protein (TAB) 1. PLoS ONE 2011, 6, e29256.
84. Theivanthiran, B.; Kathania, M.; Zeng, M.; Anguiano, E.; Basrur, V.; Vandergriff, T.; Pascual, V.; Wei, W.Z.; Massoumi, R.; Venuprasad, K. The E3 ubiquitin ligase itch inhibits p38α signaling and skin inflammation through the ubiquitylation of TAB1. Sci. Signal. 2015, 8, ra22.
85. Wang, X.; Jiang, J.; Lu, Y.; Shi, G.; Liu, R.; Cao, Y. TAB2, an important upstream adaptor of interleukin-1 signaling pathway, is subject to sumoylation. Mol. Cell. Biochem. 2014, 385, 69–77.
86. Hu, M.M.; Yang, Q.; Zhang, J.; Liu, S.M.; Zhang, Y.; Lin, H.; Huang, Z.F.; Wang, Y.Y.; Zhang, X.D.; Zhong, B., et al. TRIM38 inhibits TNFα-and IL-1β-triggered NF-B activation by mediating lysosome-dependent degradation of TAB2/3. Proc. Natl. Acad. Sci. USA 2014, 111, 1509–1514.
87. Kirkin, V.; McEwan, D.G.; Novak, I.; Dikic, I. A role for ubiquitin in selective autophagy. Mol. Cell 2009, 34, 259–269.
88. Tao, T.; He, Z.; Shao, Z.; Lu, H. TAB3 O-GlcNAcylation promotes metastasis of triple negative breast cancer. Oncotarget 2016, 7, 22807–22818.
89. Zhang, L.; Ding, X.; Cui, J.; Xu, H.; Chen, J.; Gong, Y.N.; Hu, L.; Zhou, Y.; Ge, J.; Lu, Q., et al. Cysteine methylation disrupts ubiquitin-chain sensing in NF-B activation. Nature 2012, 481, 204–208.
90. Zhang, Y.; Muhlen, S.; Oates, C.V.; Pearson, J.S.; Hartland, E.L. Identification of a distinct substrate-binding domain in the bacterial cysteine methyltransferase effectors NleE and OspZ. J. Biol. Chem. 2016, 291, 20149–20162.
91. Tian, Y.; Zhang, Y.; Zhong, B.; Wang, Y.Y.; Diao, F.C.; Wang, R.P.; Zhang, M.; Chen, D.Y.; Zhai, Z.H.; Shu, H.B. RBCK1 negatively regulates tumor necrosis factor-and interleukin-1-triggered NF-B activation by targeting TAB2/3 for degradation. J. Biol. Chem. 2007, 282, 16776–16782.
92. Scholz, R.; Sidler, C.L.; Thali, R.F.; Winssinger, N.; Cheung, P.C.; Neumann, D. Autoactivation of transforming growth factor β-activated kinase 1 is a sequential bimolecular process. J. Biol. Chem. 2010, 285, 25753–25766.
93. Singhirunnusorn, P.; Suzuki, S.; Kawasaki, N.; Saiki, I.; Sakurai, H. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-β-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J. Biol. Chem. 2005, 280, 7359–7368.
94. Prickett, T.D.; Ninomiya-Tsuji, J.; Broglie, P.; Muratore-Schroeder, T.L.; Shabanowitz, J.; Hunt, D.F.; Brautigan, D.L. TAB4 stimulates TAK1–TAB1 phosphorylation and binds polyubiquitin to direct signaling to NF-B. J. Biol. Chem. 2008, 283, 19245–19254.
95. Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67, 425–479.
96. Komander, D.; Rape, M. The ubiquitin code. Annu. Rev. Biochem. 2012, 81, 203–229.
97. Ikeda, F.; Dikic, I. Atypical ubiquitin chains: New molecular signals. EMBO Rep. 2008, 9, 536–542.
98. Rieser, E.; Cordier, S.M.; Walczak, H. Linear ubiquitination: A newly discovered regulator of cell signalling. Trends Biochem. Sci. 2013, 38, 94–102.
99. Shi, M.; Deng, W.; Bi, E.; Mao, K.; Ji, Y.; Lin, G.; Wu, X.; Tao, Z.; Li, Z.; Cai, X., et al. TRIM30 α negatively regulates TLR-mediated NF-B activation by targeting TAB2 and TAB3 for degradation. Nat. Immunol. 2008, 9, 369–377.
100. Qiu, H.; Huang, F.; Xiao, H.; Sun, B.; Yang, R. TRIM22 inhibits the TRAF6-stimulated NF-B pathway by targeting TAB2 for degradation. Virol. Sin. 2013, 28, 209–215.
101. Tan, B.; Mu, R.; Chang, Y.; Wang, Y.B.; Wu, M.; Tu, H.Q.; Zhang, Y.C.; Guo, S.S.; Qin, X.H.; Li, T., et al. RNF4 negatively regulates NF-B signaling by down-regulating TAB2. FEBS Lett. 2015, 589, 2850–2858.
102. Settembre, C.; Fraldi, A.; Medina, D.L.; Ballabio, A. Signals from the lysosome: A control centre for cellular clearance and energy metabolism. Nat. Rev. Mol. Cell Biol. 2013, 14, 283–296.
103. Kerscher, O.; Felberbaum, R.; Hochstrasser, M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 2006, 22, 159–180.
104. Drazic, A.; Myklebust, L.M.; Ree, R.; Arnesen, T. The world of protein acetylation. Biochim. Biophys. Acta 2016, 1864, 1372–1401.
105. Mittal, R.; Peak-Chew, S.Y.; McMahon, H.T. Acetylation of MEK2 and IB kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc. Natl. Acad. Sci. USA 2006, 103, 18574–18579.
106. Mukherjee, S.; Keitany, G.; Li, Y.; Wang, Y.; Ball, H.L.; Goldsmith, E.J.; Orth, K. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 2006, 312, 1211–1214.
107. Biggar, K.K.; Li, S.S. Non-histone protein methylation as a regulator of cellular signalling and function. Nat. Rev. Mol. Cell Biol. 2015, 16, 5–17.
108. Hardiville, S.; Hart, G.W. Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. Cell Metab. 2014, 20, 208–213.
109. Alfaro, J.F.; Gong, C.X.; Monroe, M.E.; Aldrich, J.T.; Clauss, T.R.; Purvine, S.O.; Wang, Z.; Camp, D.G.; Shabanowitz, J.; Stanley, P., et al. Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc. Natl. Acad. Sci. USA 2012, 109, 7280–7285.
110. Trinidad, J.C.; Barkan, D.T.; Gulledge, B.F.; Thalhammer, A.; Sali, A.; Schoepfer, R.; Burlingame, A.L. Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol. Cell. Proteom. 2012, 11, 215–229.
111. Nagel, A.K.; Schilling, M.; Comte-Walters, S.; Berkaw, M.N.; Ball, L.E. Identification of O-linked N-acetylglucosamine (O-GlcNAc)-modified osteoblast proteins by electron transfer dissociation tandem mass spectrometry reveals proteins critical for bone formation. Mol. Cell. Proteom. 2013, 12, 945–955.
112. Komatsu, Y.; Shibuya, H.; Takeda, N.; Ninomiya-Tsuji, J.; Yasui, T.; Miyado, K.; Sekimoto, T.; Ueno, N.; Matsumoto, K.; Yamada, G. Targeted disruption of the TAB1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis. Mech. Dev. 2002, 119, 239–249.
113. Sanjo, H.; Takeda, K.; Tsujimura, T.; Ninomiya-Tsuji, J.; Matsumoto, K.; Akira, S. TAB2 is essential for prevention of apoptosis in fetal liver but not for interleukin-1 signaling. Mol. Cell. Biol. 2003, 23, 1231–1238.
114. Sato, S.; Sanjo, H.; Takeda, K.; Ninomiya-Tsuji, J.; Yamamoto, M.; Kawai, T.; Matsumoto, K.; Takeuchi, O.; Akira, S. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 2005, 6, 1087–1095.
115. Jadrich, J.L.; O’Connor, M.B.; Coucouvanis, E. The TGF-β activated kinase TAK1 regulates vascular development in vivo. Development 2006, 133, 1529–1541.
116. Sakurai, H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 2012, 33, 522–530.
117. Ma, F.Y.; Tesch, G.H.; Ozols, E.; Xie, M.; Schneider, M.D.; Nikolic-Paterson, D.J. TGF-β1-activated kinase-1 regulates inflammation and fibrosis in the obstructed kidney. Am. J. Physiol. Ren. Physiol. 2011, 300, 1410–1421.
118. Zhao, Y.G.; Wang, Y.; Hao, W.; Wan, Y.Y. An essential role for TAK1 in the contact hypersensitivity response. Cell. Mol. Immunol. 2011, 8, 315–324.
119. Neubert, M.; Ridder, D.A.; Bargiotas, P.; Akira, S.; Schwaninger, M. Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ. 2011, 18, 1521–1530.
120. Wade, E.M.; Daniel, P.B.; Jenkins, Z.A.; McInerney-Leo, A.; Leo, P.; Morgan, T.; Addor, M.C.; Ades, L.C.; Bertola, D.; Bohring, A., et al. Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontometaphyseal dysplasia. Am. J. Hum. Genet. 2016, 99, 392–406.